PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY
NCT00263523 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2017-07-02
Summary
This study will use positron emission tomography (PET) and magnetic resonance imaging (MRI) to measure a serotonin receptor subtype in the brain called 5-HT(1A). This receptor is a target for drug therapy to treat anxiety and depression. The study will see if a newly developed radioligand (radioactive substance used in PET scanning to study the receptor systems of the brain) called \[(11)C\](-)-RWAY is more effective than other radioligands currently used in brain receptor research.
Healthy subjects 18-40 years of age may be eligible for this study. Candidates are screened with a physical examination, electrocardiogram, and blood and urine tests.
Participants undergo PET and MRI scanning as follows:
PET scan
PET uses small amounts of a radioactive chemical called a tracer (in this case, \[(11)C\](-)-RWAY) that "labels" active areas of the brain. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the subject's head and attached to the bed to help keep the head still during the scan so the images will be clear. A brief scan is done just before the tracer is injected to provide measures of the brain that will help in the precise calculation of information from subsequent scans. Then, the tracer is injected through a catheter (plastic tube) placed in the arm and pictures are taken for about 2 hours, while the subject lies still on the scanner bed. Subjects return to the clinic for blood and urine tests 24 hours after the scan.
MRI
The MRI scan is done within 1 year of the PET scan. MRI uses a magnetic field and radio waves to produce images of body tissues and organs-in this case, the brain. The subject lies on a table that is moved into the scanner (a tube-like device), wearing earplugs to muffle the noise of the machine during the scanning process. The space in the scanner is confining and may cause some people to be somewhat anxious. An intercom system allows the subject to speak with the staff member performing the study at all times during the procedure, and the procedure can be stopped at any time.
Conditions
- Healthy Volunteers
Interventions
- DRUG
-
[11C] (-)-RWAY
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-12-05
- Completion
- 2007-08-15
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
NCT01461083 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX
NCT02230592 ·Status: COMPLETED
-
Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)
NCT03324646 ·Status: COMPLETED
-
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
NCT00001771 ·Status: COMPLETED
-
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
NCT00527579 ·Status: COMPLETED ·Phase: PHASE1
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
NCT05357612 ·Status: RECRUITING ·Phase: PHASE4
-
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder
NCT00025974 ·Status: COMPLETED
-
[18F]-F13640 as a New Brain Radiopharmaceutical
NCT03347331 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A
NCT01198197 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Serotonin Receptors in Seizure Disorders
NCT00001932 ·Status: COMPLETED
-
To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers
NCT01253655 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
NCT05360082 ·Status: RECRUITING ·Phase: NA
-
PET Neuroimaging of [11C]Mirtazapine
NCT00288782 ·Status: COMPLETED ·Phase: PHASE4
-
Novel in Vivo Synaptic Imaging in Experienced Meditators
NCT05418608 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Dopamine in Healthy Study Participants
NCT00062946 ·Status: COMPLETED ·Phase: PHASE2
-
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
NCT00397111 ·Status: RECRUITING
-
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
NCT03898297 ·Status: ACTIVE_NOT_RECRUITING
-
Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)
NCT03030391 ·Status: TERMINATED ·Phase: PHASE1
-
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
NCT01730781 ·Status: RECRUITING
-
Serotonin Transporters in Obsessive-Compulsive-Related Disorders
NCT00082550 ·Status: COMPLETED
-
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
NCT05224115 ·Status: COMPLETED
-
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
NCT05630963 ·Status: RECRUITING
-
Precision Functional Brain Mapping in Psilocybin
NCT04501653 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neuroimaging Studies of Reward Processing in Depression
NCT03026036 ·Status: COMPLETED
-
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203
NCT00538798 ·Status: COMPLETED ·Phase: PHASE1